Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel.

Slides:

Advertisements

Similar presentations

Long-term outcome of patients in the LNH-98

Advertisements

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

Combination therapy for adult T-cell leukemia–xenografted mice: flavopiridol and anti-CD25 monoclonal antibody by Meili Zhang, Zhuo Zhang, Carolyn K. Goldman,

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular.

Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy by Caroline Besson, Aicha Goubar, Jean Gabarre, Willy Rozenbaum,

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Juvenile Myelomonocytic Leukemia

Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide.

NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura by Evaren E. Page, Johanna A. Kremer.

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma by Alexandra Albertsson-Lindblad, Arne Kolstad,

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive.

CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies

Volume 138, Issue 5, Pages e2 (May 2010)

Stage C or not stage C…? by Claire Dearden Blood

Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study Inpyo.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

by Michael F. Leahy, and J. Harvey Turner

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

by J. Evan Sadler Blood Volume 112(1):11-18 July 1, 2008

Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.

How I treat catastrophic thrombotic syndromes

A Strong Expression of CD44-6v Correlates With Shorter Survival of Patients With Acute Myeloid Leukemia by S. Legras, U. Günthert, R. Stauder, F. Curt,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Circulating CLA+ T cells from Acute and Chronic Psoriasis Patients Manifest a Different Activation State and Correlation with Disease Severity and Extension

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,

Figure 1 BG-12 treatment reduced total circulating B cells and had variable effects on memory B cells BG-12 treatment reduced total circulating B cells.

by Wendy Lim, Sara K. Vesely, and James N. George

by Sumita Ratnasingam, Patricia A. Walker, Huy Tran, Zane S

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion Franck E. Nicolini, Eric Wattel, Anne-Sophie.

Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Kaplan-Meier plots of the duration of continuous albuterol, time until q4 albuterol, and hospital LOS for each of the 4 treatment groups. Kaplan-Meier.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Thrombotic thrombocytopenic purpura

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML by Jorge E. Cortes, Martin S. Tallman, Gary.

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment by Waleed Ghanima, Bertrand Godeau,

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Cold agglutinin disease

Outcomes in patients with PTCL

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Presentation transcript:

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel Galicier, François Provôt, Claire Presne, Pascale Poullin, Guy Bonmarchand, Alain Wynckel, Ygal Benhamou, Philippe Vanhille, Aude Servais, Dominique Bordessoule, Jean-Philippe Coindre, Mohamed Hamidou, Jean-Paul Vernant, Agnès Veyradier, Paul Coppo, and Blood Volume 124(2):204-210 July 10, 2014 ©2014 by American Society of Hematology

Study flowchart. Study flowchart. Miguel Hie et al. Blood 2014;124:204-210 ©2014 by American Society of Hematology

ADAMTS13 activity and CD19+ lymphocytes during follow-up. ADAMTS13 activity and CD19+ lymphocytes during follow-up. (A) ADAMTS13 activity (%) and (B) CD19+ B lymphocytes at 0, 1, 3, 6, 9, 12, 18, and 24 months after the first preemptive rituximab course. Box plots represent quartiles, median, and range of laboratory measurements. The black line represents the variation of the mean over time. Circulating B cells were counted after mononuclear cell labeling with anti-CD19 antibodies. Cell-surface labeling was analyzed on a FACScan flow cytometer (Becton-Dickinson, San Jose, CA). Data were acquired from 104 cells in list mode and analyzed by using CellQuest software (Becton-Dickinson). Data are the mean ± standard deviation. Miguel Hie et al. Blood 2014;124:204-210 ©2014 by American Society of Hematology

Kaplan-Meier survival estimates of relapse-free survival. Kaplan-Meier survival estimates of relapse-free survival. Survival of patients with TTP who received (n = 30; group 1) or did not receive (n = 18; group 2) preemptive rituximab was compared with the Kaplan-Meier estimator. Miguel Hie et al. Blood 2014;124:204-210 ©2014 by American Society of Hematology

Outcome in patients with TTP according to treatment. Outcome in patients with TTP according to treatment. Patients of group 1 (n = 30) received preemptive rituximab; patients of group 2 (n = 18) did not. Miguel Hie et al. Blood 2014;124:204-210 ©2014 by American Society of Hematology